Alpha Cognition Inc (ACOG)vsBeiGene, Ltd. (ONC)
ACOG
Alpha Cognition Inc
$5.32
-4.83%
HEALTHCARE · Cap: $124.15M
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 71839% more annual revenue ($5.34B vs $7.43M). ONC leads profitability with a 5.4% profit margin vs -2.6%. ONC earns a higher WallStSmart Score of 42/100 (D).
ACOG
Avoid20
out of 100
Grade: F
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ACOG.
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -125.6% — below average capital efficiency
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ACOG
The strongest argument for ACOG centers on Price/Book.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : ACOG
The primary concerns for ACOG are Revenue Growth, EPS Growth, Market Cap.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Key Dynamics to Monitor
ACOG profiles as a turnaround stock while ONC is a hypergrowth play — different risk/reward profiles.
ACOG carries more volatility with a beta of 2.55 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 20/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alpha Cognition Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alpha Cognition Inc. is a pioneering biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases, with a strong emphasis on Alzheimer's disease. Its lead candidate, ACOG-100, is designed to enhance cognitive function in patients and address significant unmet medical needs within the aging population. Driven by a robust R&D strategy and a proprietary neuroscience platform, Alpha Cognition is strategically positioned to revolutionize patient care in this critical area. As the company continues to advance its clinical pipeline and explore new therapeutic avenues, it represents a compelling opportunity for institutional investors navigating the evolving healthcare landscape.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?